Raphael J Landovitz

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Biomedical Prevention for HIV in High-risk Populations with Comorbidities
    NIH K23DA026308Sep 1, 2009 - Jun 30, 2014
    Role: Principal Investigator
    UCLA AIDS Prevention and Treatment Clinical Trials Unit
    NIH UM1AI069424Feb 1, 2007 - Nov 30, 2027
    Role: Co-Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial. Lancet HIV. 2024 Dec 09. Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton KE, Domin E, Lin BC, McKee K, Doria-Rose N, Regenold S, Spiegel H, Anderson M, McClosky N, Zhang L, Piwowar-Manning E, Ackerman ME, Pensiero M, Dye BJ, Landovitz RJ, Mayer K, Siegel M, Sobieszczyk M, Walsh SR, Gama L, Barouch DH, Montefiori DC, Tomaras GD, HVTN 136/HPTN 092 Study Team. PMID: 39667379.
      View in: PubMed   Mentions:    Fields:    
    2. Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2024 Dec 01. Gandhi RT, Landovitz RJ, Sax PE, Smith DM, Springer SA, Günthard HF, Thompson MA, Bedimo RJ, Benson CA, Buchbinder SP, Crabtree-Ramirez BE, Del Rio C, Eaton EF, Eron JJ, Hoy JF, Lehmann C, Molina JM, Jacobsen DM, Saag MS. PMID: 39616604.
      View in: PubMed   Mentions:    Fields:    
    3. Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial STIs: A Secondary Analysis of HPTN 083. Clin Infect Dis. 2024 Nov 23. Clement ME, Hanscom B, Haines D, Bazan JA, Chotirosniramit N, Kofron R, Mannheimer S, Mayer KH, Torres Silva MS, Soto-Torres L, Rinehart AR, Rooney JF, Jennings A, Gomez-Feliciano K, McCauley M, Grinsztejn B, Landovitz RJ, for HPTN 083 Study Team . PMID: 39579334.
      View in: PubMed   Mentions:    Fields:    
    4. Type 1 Human Immunodeficiency Virus (HIV-1) Incidence, Adherence, and Drug Resistance in Individuals Taking Daily Emtricitabine/Tenofovir Disoproxil Fumarate for HIV-1 Pre-exposure Prophylaxis: Pooled Analysis From 72 Global Studies. Clin Infect Dis. 2024 Nov 22; 79(5):1197-1207. Landovitz RJ, Tao L, Yang J, de Boer M, Carter C, Das M, Baeten JM, Liu A, Hoover KW, Celum C, Grinsztejn B, Morris S, Wheeler DP, Mayer KH, Golub SA, Bekker LG, Diabaté S, Hoornenborg E, Myers J, Leech AA, McCormack S, Chan PA, Sweat M, Matthews LT, Grant R, Global F/TDF PrEP Study Team . PMID: 38484128; PMCID: PMC7616831.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    5. Protocol for a randomized controlled trial with a stepped care approach, utilizing PrEP navigation with and without contingency management, for transgender women and sexual minority men with a substance use disorder: Assistance Services Knowledge-PrEP (A.S.K.-PrEP). Addict Sci Clin Pract. 2024 Nov 09; 19(1):79. Reback CJ, Landovitz RJ, Benkeser D, Jalali A, Shoptaw S, Li MJ, Mata RP, Ryan D, Jeng PJ, Murphy SM. PMID: 39521970; PMCID: PMC11549772.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    6. HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084. AIDS Res Hum Retroviruses. 2024 Oct 28. Fogel JM, Persaud D, Piwowar-Manning E, Richardson P, Szewczyk J, Marzinke MA, Wang Z, Guo X, McCauley M, Farrior J, Tran HV, Ungsedhapand C, Mathew CA, Mpendo J, Rinehart AR, Rooney JF, Cohen MS, Hanscom B, Grinsztejn B, Hosseinipour MC, Delany-Moretlwe S, Landovitz RJ, Eshleman SH, HPTN 083 and HPTN 084 Study Teams. PMID: 39466048.
      View in: PubMed   Mentions:    Fields:    
    7. Pharmacologic Drug Detection and Self-Reported Adherence in the HPTN069/ACTG5305 Phase II PrEP Trial. AIDS Behav. 2024 Nov; 28(11):3710-3718. Cooper SE, Zhang S, Haines D, Mayer KH, Amico KR, Landovitz RJ, Hendrix CW, Marzinke MA, Chege W, McCauley M, Gulick RM. PMID: 39083151; PMCID: PMC11471692.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    8. Features of HIV Infection in the Context of Long-Acting Cabotegravir Preexposure Prophylaxis. N Engl J Med. 2024 Oct 03; 391(13):1253-1256. Landovitz RJ, Delany-Moretlwe S, Fogel JM, Marzinke MA, Piwowar-Manning E, Richardson P, Halvas EK, Mellors JW, Persaud D, Kofron R, McCauley M, Rose S, Rinehart AR, Rooney JF, Adeyeye A, Cohen MS, Donnell D, Hosseinipour MC, Grinsztejn B, Eshleman SH, HPTN 083 and 084 Study Teams. PMID: 39046350; PMCID: PMC11598663.
      View in: PubMed   Mentions:    Fields:    
    9. Evaluation of Xpert point-of-care assays for detection of HIV infection in persons using long-acting cabotegravir for pre-exposure prophylaxis. Microbiol Spectr. 2024 Jul 09; e0030724. Fogel JM, Piwowar-Manning E, Moser A, Hill T, Ahmed S, Cummings V, Mostafa HH, Wang Z, Jennings A, Gallardo-Cartagena JA, Figueroa MI, St Clair M, Rinehart AR, Adeyeye A, Rooney JF, Cohen MS, Grinsztejn B, Landovitz RJ, Eshleman SH, HPTN 083 Study Team. PMID: 38980027; PMCID: PMC11302132.
      View in: PubMed   Mentions:    Fields:    
    10. The impact of intimate partner violence on PrEP adherence among U.S. Cisgender women at risk for HIV. BMC Public Health. 2024 May 31; 24(1):1461. Anderson KM, Blumenthal J, Jain S, Sun X, Amico KR, Landovitz R, Zachek CM, Morris S, Moore DJ, Stockman JK. PMID: 38822300; PMCID: PMC11140862.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    11. Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP. Antimicrob Agents Chemother. 2024 May 06; e0147523. Han K, Patel P, McCallister S, Rinehart AR, Gandhi Y, Spreen W, Landovitz RJ, Delany-Moretlwe S, Marzinke MA, McKeon T, Budnik P, van Wyk J, Ford SL. PMID: 38709006.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    12. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study. J Int AIDS Soc. 2024 May; 27(5):e26252. Psaros C, Goodman GR, Lee JS, Rice W, Kelley CF, Oyedele T, Coelho LE, Phanuphak N, Singh Y, Middelkoop K, Griffith S, McCauley M, Rooney J, Rinehart AR, Clark J, Go V, Sugarman J, Fields SD, Adeyeye A, Grinsztejn B, Landovitz RJ, Safren SA, HPTN 083-02 Study Team. PMID: 38783534; PMCID: PMC11116478.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    13. Daily Oral HIV Pre-exposure Prophylaxis Among Young Men Who Have Sex With Men in the United States: Cost-saving at Generic Drug Price. Clin Infect Dis. 2024 02 17; 78(2):402-410. Amick AK, Eskibozkurt GE, Hosek SG, Flanagan CF, Landovitz RJ, Jin EY, Wilson CM, Freedberg KA, Weinstein MC, Kazemian P, Paltiel AD, Ciaranello AL, Neilan AM. PMID: 37823865; PMCID: PMC10874274.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    14. Influence of Participant Perceptions of Adherence-Related Interactions with Study/Study Team on Drug Levels: HPTN069 Analysis of Self-Reported Adherence Experiences While on Study. AIDS Behav. 2024 Mar; 28(3):1058-1067. Amico KR, Mayer KH, Landovitz RJ, Marzinke M, Hendrix C, McCauley M, Wilkin T, Gulick R, HPTN 069/A5305 study team. PMID: 37947968; PMCID: PMC10896804.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    15. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial. Lancet HIV. 2023 12; 10(12):e767-e778. Landovitz RJ, Hanscom BS, Clement ME, Tran HV, Kallas EG, Magnus M, Sued O, Sanchez J, Scott H, Eron JJ, Del Rio C, Fields SD, Marzinke MA, Eshleman SH, Donnell D, Spinelli MA, Kofron RM, Berman R, Piwowar-Manning EM, Richardson PA, Sullivan PA, Lucas JP, Anderson PL, Hendrix CW, Adeyeye A, Rooney JF, Rinehart AR, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team. PMID: 37952550; PMCID: PMC11375758.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsPHPublic Health
    16. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial. Lancet HIV. 2023 11; 10(11):e703-e712. Marzinke MA, Hanscom B, Wang Z, Safren SA, Psaros C, Donnell D, Richardson PA, Sullivan P, Eshleman SH, Jennings A, Feliciano KG, Jalil E, Coutinho C, Cardozo N, Maia B, Khan T, Singh Y, Middelkoop K, Franks J, Valencia J, Sanchez N, Lucas J, Rooney JF, Rinehart AR, Ford S, Adeyeye A, Cohen MS, McCauley M, Landovitz RJ, Grinsztejn B, HPTN 083 study group. PMID: 37783219; PMCID: PMC10842527.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    17. Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis. AIDS. 2023 09 01; 37(11):1711-1714. Hazra A, Landovitz RJ, Marzinke MA, Quinby C, Creticos C. PMID: 37418423.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    18. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023 10; 21(10):657-670. Landovitz RJ, Scott H, Deeks SG. PMID: 37344551.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    19. A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS-CoV-2(-)/(+) populations. Clin Transl Sci. 2023 07; 16(7):1243-1257. Steinbronn C, Chhonker YS, Stewart J, Leingang H, Heller KB, Krows ML, Paasche-Orlow M, Bershteyn A, Stankiewicz Karita HC, Agrawal V, Laufer M, Landovitz R, Wener M, Murry DJ, Johnston C, Barnabas RV, Arnold SLM. PMID: 37118968; PMCID: PMC10339702.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    20. Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV. Glob Health Sci Pract. 2023 04 28; 11(2). Ruel T, Penazzato M, Zech JM, Archary M, Cressey TR, Goga A, Harwell J, Landovitz RJ, Lain MG, Lallemant M, Namusoke-Magongo E, Mukui I, Permar SR, Prendergast AJ, Shapiro R, Abrams EJ. PMID: 37116934; PMCID: PMC10141432.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansPHPublic Health
    21. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. Antimicrob Agents Chemother. 2023 04 18; 67(4):e0005323. Marzinke MA, Fogel JM, Wang Z, Piwowar-Manning E, Kofron R, Moser A, Bhandari P, Gollings R, Bushman LR, Weng L, Halvas EK, Mellors J, Anderson PL, Persaud D, Hendrix CW, McCauley M, Rinehart AR, St Clair M, Ford SL, Rooney JF, Adeyeye A, Chariyalertsak S, Mayer K, Arduino RC, Cohen MS, Grinsztejn B, Hanscom B, Landovitz RJ, Eshleman SH. PMID: 36995219; PMCID: PMC10112247.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    22. Development and validation of a liquid chromatographic-tandem mass spectrometric assay for the quantification of cabotegravir and rilpivirine from dried blood spots. J Pharm Biomed Anal. 2023 May 10; 228:115307. Weld ED, Parsons TL, Gollings R, McCauley M, Grinsztejn B, Landovitz RJ, Marzinke MA. PMID: 36842333; PMCID: PMC10065945.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083. Lancet Reg Health Am. 2023 Feb; 18:100416. Mitchell KM, Boily MC, Hanscom B, Moore M, Todd J, Paz-Bailey G, Wejnert C, Liu A, Donnell DJ, Grinsztejn B, Landovitz RJ, Dimitrov DT. PMID: 36844011; PMCID: PMC9950652.
      View in: PubMed   Mentions: 3  
    24. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study. Lancet HIV. 2023 04; 10(4):e254-e265. Smith J, Bansi-Matharu L, Cambiano V, Dimitrov D, Bershteyn A, van de Vijver D, Kripke K, Revill P, Boily MC, Meyer-Rath G, Taramusi I, Lundgren JD, van Oosterhout JJ, Kuritzkes D, Schaefer R, Siedner MJ, Schapiro J, Delany-Moretlwe S, Landovitz RJ, Flexner C, Jordan M, Venter F, Radebe M, Ripin D, Jenkins S, Resar D, Amole C, Shahmanesh M, Gupta RK, Raizes E, Johnson C, Inzaule S, Shafer R, Warren M, Stansfield S, Paredes R, Phillips AN, HIV Modelling Consortium. PMID: 36642087; PMCID: PMC10065903.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    25. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2023 01 03; 329(1):63-84. Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, Benson CA, Buchbinder SP, Del Rio C, Eron JJ, Günthard HF, Molina JM, Jacobsen DM, Saag MS. PMID: 36454551.
      View in: PubMed   Mentions: 145     Fields:    Translation:HumansCells
    26. HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention. J Infect Dis. 2022 12 13; 226(12):2170-2180. Eshleman SH, Fogel JM, Halvas EK, Piwowar-Manning E, Marzinke MA, Kofron R, Wang Z, Mellors J, McCauley M, Rinehart AR, St Clair M, Adeyeye A, Hinojosa JC, Cabello R, Middelkoop K, Hanscom B, Cohen MS, Grinsztejn B, Landovitz RJ, HPTN 083 Study Team. PMID: 36240386; PMCID: PMC10205624.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    27. A community-partnered approach for diversity in COVID-19 vaccine clinical trials. J Clin Transl Sci. 2023; 7(1):e23. Castellon-Lopez Y, Landovitz R, Ntekume E, Porter C, Bross R, Hilder R, Lucas-Wright A, Daar ES, Chavez P, Blades C, Carson S, Morris D, Vassar S, Casillas A, Brown A. PMID: 36714798; PMCID: PMC9874035.
      View in: PubMed   Mentions: 6  
    28. Engagement With HIV and COVID-19 Prevention: Nationwide Cross-sectional Analysis of Users on a Geosocial Networking App. J Med Internet Res. 2022 09 22; 24(9):e38244. Gaither TW, Sigalos JT, Landovitz RJ, Mills JN, Litwin MS, Eleswarapu SV. PMID: 36026586; PMCID: PMC9512083.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    29. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. AIDS Res Hum Retroviruses. 2022 11; 38(11):840-846. Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz R, Reirden D, Glenny C, Malhotra M, Anderson PL, Hosek S. PMID: 35943868; PMCID: PMC9910104.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    30. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine. AIDS Behav. 2023 Jan; 27(1):10-24. Edwards GG, Miyashita-Ochoa A, Castillo EG, Goodman-Meza D, Kalofonos I, Landovitz RJ, Leibowitz AA, Pulsipher C, El Sayed E, Shoptaw S, Shover CL, Tabajonda M, Yang YS, Harawa NT. PMID: 36063243; PMCID: PMC9443641.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    31. Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. Clin Trials. 2022 12; 19(6):605-612. Hanscom BS, Donnell DJ, Fleming TR, Hughes JP, McCauley M, Grinsztejn B, Landovitz RJ, Emerson SS. PMID: 36053045; PMCID: PMC9691580.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    32. Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study. Clin Infect Dis. 2022 08 24; 75(1):e1180-e1183. Bershteyn A, Dahl AM, Dong TQ, Deming ME, Celum CL, Chu HY, Kottkamp AC, Greninger AL, Hoffman RM, Jerome KR, Johnston CM, Kissinger PJ, Landovitz RJ, Laufer MK, Luk A, Neuzil KM, Paasche-Orlow MK, Pitts RA, Schwartz MD, Stankiewicz Karita HC, Thorpe LE, Wald A, Zheng CY, Wener MH, Barnabas RV, Brown ER. PMID: 35152299; PMCID: PMC8903379.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    33. Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19. J Med Virol. 2022 12; 94(12):6091-6096. Kumbhakar R, Neradilek M, Barnabas RV, Stewart J, Stankiewicz Karita HC, Landovitz RJ, Kissinger PJ, Jerome KR, Paasche-Orlow MK, Bershteyn A, Chu HY, Neuzil KM, Greninger AL, Luk A, Wald A, Brown ER, Johnston C. PMID: 35940869; PMCID: PMC9538473.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    34. A population pharmacokinetic model based on HPTN 077 of long-acting injectable cabotegravir for HIV PrEP. Br J Clin Pharmacol. 2022 10; 88(10):4623-4632. Yu Y, Bigos KL, Marzinke MA, Landovitz RJ, McCauley M, Ford S, Hendrix CW, Bies RR, Weld ED, HPTN 077 Study Team. PMID: 35949044; PMCID: PMC10077525.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses. 2022 12; 38(12):939-943. Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz RJ, Reirden D, Malhotra M, Glenny C, Harding P, Powell T, Anderson PL, Hosek S. PMID: 35815468; PMCID: PMC9910105.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    36. Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects. Br J Clin Pharmacol. 2022 10; 88(10):4607-4622. Han K, Baker M, Lovern M, Paul P, Xiong Y, Patel P, Moore KP, Seal CS, Cutrell AG, D'Amico RD, Benn PD, Landovitz RJ, Marzinke MA, Spreen WR, Ford SL. PMID: 35695476; PMCID: PMC9543358.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    37. Sexual behavior and medication adherence in men who have sex with men participating in a pre-exposure prophylaxis study of combinations of Maraviroc, Tenofovir Disoproxil Fumarate and/or Emtricitabine (HPTN 069/ACTG 5305). AIDS Behav. 2022 Dec; 26(12):4107-4114. Mayer KH, Yuhas K, Amico KR, Wilkin T, Landovitz RJ, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Cottle LM, Marcus C, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu AY, Frank I, Ho K, Santana J, Stekler JD, Chen YQ, McCauley M, Gulick RM, HPTN 069/ACTG 5305 Study Team. PMID: 35687192; PMCID: PMC10265494.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    38. Low incidence and prevalence of hepatitis C in two cohorts of HIV pre-exposure prophylaxis adherence interventions in men who have sex with men in Southern California. J Viral Hepat. 2022 07; 29(7):529-535. Hassan A, Agustin HGS, Burke L, Kofron R, Corado K, Bolan R, Landovitz RJ, Dubé MP, Morris SR. PMID: 35357767; PMCID: PMC9908082.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsPHPublic Health
    39. Promises and challenges: cabotegravir for preexposure prophylaxis. Curr Opin HIV AIDS. 2022 07 01; 17(4):186-191. Spinelli MA, Grinsztejn B, Landovitz RJ. PMID: 35762372; PMCID: PMC9240402.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    40. Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: A qualitative study exploring the anticipated challenges and opportunities for implementation in Los Angeles County. PLoS One. 2022; 17(2):e0262926. Jolayemi O, Bogart LM, Storholm ED, Goodman-Meza D, Rosenberg-Carlson E, Cohen R, Kao U, Shoptaw S, Landovitz RJ. PMID: 35113892; PMCID: PMC8812879.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    41. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305. J Antimicrob Chemother. 2022 02 02; 77(2):500-506. Brown TT, Yuhas K, Mayer KH, Landovitz RJ, Marzinke MA, Hendrix CW, Chen YQ, Klingman KL, Chege W, Mccauley MB, Gulick RM, Wilkin TJ. PMID: 34791296; PMCID: PMC9097256.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis. Ann Intern Med. 2022 04; 175(4):479-489. Neilan AM, Landovitz RJ, Le MH, Grinsztejn B, Freedberg KA, McCauley M, Wattananimitgul N, Cohen MS, Ciaranello AL, Clement ME, Reddy KP, Hyle EP, Paltiel AD, Walensky RP. PMID: 35099992; PMCID: PMC9087297.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    43. Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. JAMA Netw Open. 2022 01 04; 5(1):e2142796. Stankiewicz Karita HC, Dong TQ, Johnston C, Neuzil KM, Paasche-Orlow MK, Kissinger PJ, Bershteyn A, Thorpe LE, Deming M, Kottkamp A, Laufer M, Landovitz RJ, Luk A, Hoffman R, Roychoudhury P, Magaret CA, Greninger AL, Huang ML, Jerome KR, Wener M, Celum C, Chu HY, Baeten JM, Wald A, Barnabas RV, Brown ER. PMID: 35006245; PMCID: PMC8749477.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    44. Pre-Exposure Prophylaxis Perspectives, Sociodemographic Characteristics, and HIV Risk Profiles of Cisgender Women Seeking and Initiating PrEP in a US Demonstration Project. AIDS Patient Care STDS. 2021 12; 35(12):481-487. Blumenthal J, Landovitz R, Jain S, He F, Kofron R, Ellorin E, Ntim GM, Stockman JK, Corado K, Rivet Amico K, Moore DJ, Morris S. PMID: 34851726; PMCID: PMC8905235.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    45. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 2021 11 16; 224(9):1581-1592. Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, Cohen MS, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ, Eshleman SH. PMID: 33740057; PMCID: PMC8599849.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansPHPublic Health
    46. Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States. Clin Infect Dis. 2021 10 05; 73(7):1149-1156. Blumenthal J, Jain S, He F, Amico KR, Kofron R, Ellorin E, Stockman JK, Psaros C, Ntim GM, Chow K, Anderson PL, Haubrich R, Corado K, Moore DJ, Morris S, Landovitz RJ. PMID: 33864370; PMCID: PMC8492205.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansPHPublic Health
    47. Cost-effectiveness of Frequent HIV Screening Among High-risk Young Men Who Have Sex With Men in the United States. Clin Infect Dis. 2021 10 05; 73(7):e1927-e1935. Neilan AM, Bulteel AJB, Hosek SG, Foote JHA, Freedberg KA, Landovitz RJ, Walensky RP, Resch SC, Kazemian P, Paltiel AD, Weinstein MC, Wilson CM, Ciaranello AL. PMID: 32730625; PMCID: PMC8492162.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Challenges and Opportunities for Preexposure Prophylaxis. Top Antivir Med. 2021 Oct-Nov; 29(4):399-406. Cambou MC, Landovitz RJ. PMID: 34856093; PMCID: PMC8670824.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic Health
    49. COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California. JAMA Netw Open. 2021 09 01; 4(9):e2127582. Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, Ntekume E, Landovitz R, Vassar SD, Norris KC, Dubinett SM, Garrison NA, Brown AF. PMID: 34591103; PMCID: PMC8485164.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    50. Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial. Lancet HIV. 2021 11; 8(11):e723-e728. Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ. PMID: 34454678; PMCID: PMC11015900.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    51. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 08 12; 385(7):595-608. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B, HPTN 083 Study Team. PMID: 34379922; PMCID: PMC8448593.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansPHPublic Health
    52. Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. AIDS. 2021 08 01; 35(10):1585-1595. Sekabira R, McGowan I, Yuhas K, Brand RM, Marzinke MA, Manabe YC, Frank I, Eron J, Landovitz RJ, Anton P, Cranston RD, Anderson P, Mayer KH, Amico KR, Wilkin TJ, Chege W, Kekitiinwa AR, McCauley M, Gulick RM, Hendrix CW. PMID: 33831911; PMCID: PMC8483241.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    53. Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study". ACS Pharmacol Transl Sci. 2021 Aug 13; 4(4):1462. Seneviratne HK, Hamlin AN, Li S, Grinsztejn B, Dawood H, Liu AY, Kuo I, Hosseinipour MC, Panchia R, Cottle L, Chau G, Adeyeye A, Rinehart AR, McCauley M, Eron JJ, Cohen MS, Landovitz RJ, Hendrix CW, Bumpus NN. PMID: 35783008; PMCID: PMC9241154.
      View in: PubMed   Mentions:
    54. "PrEP"ing for a PrEP demonstration project: understanding PrEP knowledge and attitudes among cisgender women. BMC Womens Health. 2021 05 25; 21(1):220. Pasipanodya EC, Stockman J, Phuntsog T, Morris S, Psaros C, Landovitz R, Amico KR, Moore DJ, Blumenthal J. PMID: 34034719; PMCID: PMC8146684.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    55. Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study. ACS Pharmacol Transl Sci. 2021 Feb 12; 4(1):226-239. Seneviratne HK, Hamlin AN, Li S, Grinsztejn B, Dawood H, Liu AY, Kuo I, Hosseinipour MC, Panchia R, Cottle L, Chau G, Adeyeye A, Rinehart AR, McCauley M, Eron JS, Cohen MS, Landovitz RJ, Hendrix CW, Bumpus NN. PMID: 33615175; PMCID: PMC7888308.
      View in: PubMed   Mentions: 1  
    56. Assessing the Role of Long-Acting Cabotegravir Preexposure Prophylaxis of Human Immunodeficiency Virus: Opportunities and Aspirations. J Infect Dis. 2021 01 04; 223(1):1-3. Cohen MS, Landovitz RJ. PMID: 32882042; PMCID: PMC7781443.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsPHPublic Health
    57. Taking a stand against the politicization of medical research: how 'swinging the pendulum' poses a hazard to clinical trials, study participants, and the progress of science. Expert Rev Clin Immunol. 2021 01; 17(1):101-103. Bershteyn A, Schwartz MD, Thorpe LE, Paasche-Orlow MK, Kissinger P, Stankiewicz Karita HC, Laufer MK, Hoffman RM, Landovitz RJ, Paolino K, Barnabas RV. PMID: 33284056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med. 2021 03; 174(3):344-352. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, Neuzil KM, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM, Hydroxychloroquine COVID-19 PEP Study Team. PMID: 33284679; PMCID: PMC7732017.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    59. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2020 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2020 10 27; 324(16):1651-1669. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, Smith DM, Benson CA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. PMID: 33052386; PMCID: PMC11017368.
      View in: PubMed   Mentions: 175     Fields:    Translation:HumansCellsPHPublic Health
    60. Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077. AIDS Behav. 2020 Sep; 24(9):2520-2531. Tolley EE, Zangeneh SZ, Chau G, Eron J, Grinsztejn B, Humphries H, Liu A, Siegel M, Bertha M, Panchia R, Li S, Cottle L, Rinehart A, Margolis D, Jennings A, McCauley M, Landovitz RJ. PMID: 32052214; PMCID: PMC7423859.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansPHPublic Health
    61. Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. J Acquir Immune Defic Syndr. 2020 09 01; 85(1):93-97. Blair CS, Li S, Chau G, Cottle L, Richardson P, Marzinke MA, Eshleman SH, Adeyeye A, Rinehart AR, Margolis D, McCauley M, Hendrix CW, Landovitz RJ, HPTN 077 Study Team. PMID: 32452972; PMCID: PMC7549535.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsPHPublic Health
    62. PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM. Open Forum Infect Dis. 2020 Aug; 7(8):ofaa329. Blair CS, Beymer MR, Kofron RM, Bolan RK, Jordan WC, Haubrich RH, Wohl AR, Landovitz RJ. PMID: 32851110; PMCID: PMC7442274.
      View in: PubMed   Mentions: 4  
    63. Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. PLoS One. 2020; 15(7):e0236032. Berenguer J, Parrondo J, Landovitz RJ. PMID: 32687492; PMCID: PMC7371210.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    64. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S63-S69. Neilan TG, Nguyen KL, Zaha VG, Chew KW, Morrison L, Ntusi NAB, Toribio M, Awadalla M, Drobni ZD, Nelson MD, Burdo TH, Van Schalkwyk M, Sax PE, Skiest DJ, Tashima K, Landovitz RJ, Daar E, Wurcel AG, Robbins GK, Bolan RK, Fitch KV, Currier JS, Bloomfield GS, Desvigne-Nickens P, Douglas PS, Hoffmann U, Grinspoon SK, Ribaudo H, Dawson R, Goetz MB, Jain MK, Warner A, Szczepaniak LS, Zanni MV. PMID: 32645158; PMCID: PMC7347082.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    65. Collective Call to Action for HIV/AIDS Community-Based Collaborative Science in the Era of COVID-19. AIDS Behav. 2020 07; 24(7):2013-2016. Shoptaw S, Goodman-Meza D, Landovitz RJ. PMID: 32300993; PMCID: PMC7160820.
      View in: PubMed   Mentions: 21     Fields:    
    66. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020 07; 7(7):e472-e481. Landovitz RJ, Li S, Eron JJ, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Eshleman SH, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Cohen MS, McCauley M, Hendrix CW. PMID: 32497491; PMCID: PMC7859863.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    67. Donate now to prevent sexually transmitted infections later: incentivising testing of sexually transmitted infections. Lancet Infect Dis. 2020 08; 20(8):885-886. Beymer MR, Landovitz RJ. PMID: 32530427.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    68. Novel Antiretroviral Agents. Curr HIV/AIDS Rep. 2020 04; 17(2):118-124. Cambou MC, Landovitz RJ. PMID: 32052271; PMCID: PMC7357992.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    69. Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113. Clin Infect Dis. 2020 02 03; 70(4):687-691. Havens PL, Perumean-Chaney SE, Patki A, Cofield SS, Wilson CM, Liu N, Anderson PL, Landovitz RJ, Kapogiannis BG, Hosek SG, Mulligan K. PMID: 31179503; PMCID: PMC7319267.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    70. Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077. Clin Infect Dis. 2020 01 02; 70(2):319-322. Landovitz RJ, Zangeneh SZ, Chau G, Grinsztejn B, Eron JJ, Dawood H, Magnus M, Liu AY, Panchia R, Hosseinipour MC, Kofron R, Margolis DA, Rinehart A, Adeyeye A, Burns D, McCauley M, Cohen MS, Currier JS. PMID: 31125395; PMCID: PMC6938971.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    71. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS. 2020 01; 15(1):19-26. Clement ME, Kofron R, Landovitz RJ. PMID: 31644481; PMCID: PMC7382946.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCellsPHPublic Health
    72. HIV Preexposure Prophylaxis-The Role of Primary Care Clinicians in Ending the HIV Epidemic. JAMA Intern Med. 2020 01 01; 180(1):126-130. Khalili J, Landovitz RJ. PMID: 31738380.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsPHPublic Health
    73. Factors associated with repeat rectal Neisseria gonorrhoeae and Chlamydia trachomatis screening following inconclusive nucleic acid amplification testing: A potential missed opportunity for screening. PLoS One. 2019; 14(12):e0226413. Blair CS, Garner OB, Pedone B, Elias S, Comulada WS, Landovitz RJ. PMID: 31830129; PMCID: PMC6907836.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    74. Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis. BMC Infect Dis. 2019 Nov 08; 19(1):918. Goodman-Meza D, Weiss RE, Gamboa S, Gallegos A, Bui AAT, Goetz MB, Shoptaw S, Landovitz RJ. PMID: 31699053; PMCID: PMC6839097.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    75. Initiation of antiretroviral therapy with integrase strand-transfer inhibitor-based regimens and reduction of the risk of horizontal transmission of HIV-1. EClinicalMedicine. 2019 Dec; 17:100195. Berenguer J, Parrondo J, Landovitz RJ. PMID: 31891133; PMCID: PMC6933284.
      View in: PubMed   Mentions: 1  
    76. Pre-exposure prophylaxis 2.0: new drugs and technologies in the pipeline. Lancet HIV. 2019 11; 6(11):e788-e799. Coelho LE, Torres TS, Veloso VG, Landovitz RJ, Grinsztejn B. PMID: 31558423.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansPHPublic Health
    77. Current and Future PrEP Medications and Modalities: On-demand, Injectables, and Topicals. Curr HIV/AIDS Rep. 2019 08; 16(4):349-358. Beymer MR, Holloway IW, Pulsipher C, Landovitz RJ. PMID: 31222499; PMCID: PMC6719717.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansPHPublic Health
    78. Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. PLoS One. 2019; 14(7):e0219802. Berenguer J, Parrondo J, Landovitz RJ. PMID: 31323075; PMCID: PMC6641501.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    79. Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles. AIDS Care. 2019 10; 31(10):1228-1233. Goodman-Meza D, Beymer MR, Kofron RM, Amico KR, Psaros C, Bushman LR, Anderson PL, Bolan R, Jordan WC, Rooney JF, Wohl AR, Landovitz RJ. PMID: 30894013; PMCID: PMC6663637.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    80. Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial. Clin Infect Dis. 2019 03 05; 68(6):1044-1047. Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS, AIDS Clinical Trials Group (ACTG) 5257 Study Team. PMID: 30184104; PMCID: PMC6399433.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    81. Perspectives of US women participating in a candidate PrEP study: adherence, acceptability and future use intentions. J Int AIDS Soc. 2019 03; 22(3):e25247. Amico KR, Ramirez C, Caplan MR, Montgomery BE, Stewart J, Hodder S, Swaminathan S, Wang J, Darden-Tabb NY, McCauley M, Mayer KH, Wilkin T, Landovitz RJ, Gulick R, Adimora AA, HPTN 069/A5305 Study Team and HPTN Women at Risk Committee. PMID: 30869200; PMCID: PMC6416666.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    82. Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial. AIDS Care. 2019 06; 31(6):746-753. Caplan MR, Landovitz RJ, Palanee-Phillips T, Nair G, Mhlanga F, Balkus JE, Riddler SA, Gorbach PM. PMID: 30759997; PMCID: PMC6594184.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsPHPublic Health
    83. The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. AIDS. 2019 02 01; 33(2):237-246. McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R. PMID: 30557160; PMCID: PMC6714572.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    84. No change in health-related quality of life for at-risk U.S. women and men starting HIV pre-exposure prophylaxis (PrEP): Findings from HPTN 069/ACTG A5305. PLoS One. 2018; 13(12):e0206577. Kapadia SN, Wu C, Mayer KH, Wilkin TJ, Amico KR, Landovitz RJ, Andrade A, Chen YQ, Chege W, McCauley M, Gulick RM, Schackman BR. PMID: 30586364; PMCID: PMC6306196.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    85. Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border. Am J Public Health. 2019 01; 109(1):73-82. Goodman-Meza D, Medina-Mora ME, Magis-Rodríguez C, Landovitz RJ, Shoptaw S, Werb D. PMID: 30495992; PMCID: PMC6301408.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansPHPublic Health
    86. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018 11; 15(11):e1002690. Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ. PMID: 30408115; PMCID: PMC6224042.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    87. Acceptability of Injectable and On-Demand Pre-Exposure Prophylaxis Among an Online Sample of Young Men Who Have Sex with Men in California. LGBT Health. 2018 Aug/Sep; 5(6):341-349. Beymer MR, Gildner JL, Holloway IW, Landovitz RJ. PMID: 30118399; PMCID: PMC6145037.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    88. Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir. Clin Infect Dis. 2018 08 16; 67(5):791-794. Fulcher JA, Du Y, Zhang TH, Sun R, Landovitz RJ. PMID: 29933437; PMCID: PMC6093998.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    89. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 07 24; 320(4):379-396. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. PMID: 30043070; PMCID: PMC6415748.
      View in: PubMed   Mentions: 256     Fields:    Translation:Humans
    90. Genetic Variation of the Kinases That Phosphorylate Tenofovir and Emtricitabine in Peripheral Blood Mononuclear Cells. AIDS Res Hum Retroviruses. 2018 05; 34(5):421-429. Figueroa DB, Madeen EP, Tillotson J, Richardson P, Cottle L, McCauley M, Landovitz RJ, Andrade A, Hendrix CW, Mayer KH, Wilkin T, Gulick RM, Bumpus NN. PMID: 29455571; PMCID: PMC5934973.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    91. Does HIV pre-exposure prophylaxis use lead to a higher incidence of sexually transmitted infections? A case-crossover study of men who have sex with men in Los Angeles, California. Sex Transm Infect. 2018 09; 94(6):457-462. Beymer MR, DeVost MA, Weiss RE, Dierst-Davies R, Shover CL, Landovitz RJ, Beniasians C, Talan AJ, Flynn RP, Krysiak R, McLaughlin K, Bolan RK. PMID: 29487172; PMCID: PMC6482844.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansPHPublic Health
    92. Sexually Transmitted Infection Testing of HIV-Positive Medicare and Medicaid Enrollees Falls Short of Guidelines. Sex Transm Dis. 2018 01; 45(1):8-13. Landovitz RJ, Gildner JL, Leibowitz AA. PMID: 29240633; PMCID: PMC5737450.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic Health
    93. Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California. J Acquir Immune Defic Syndr. 2017 12 15; 76(5):501-511. Landovitz RJ, Beymer M, Kofron R, Amico KR, Psaros C, Bushman L, Anderson PL, Flynn R, Lee DP, Bolan RK, Jordan WC, Tseng CH, Dierst-Davies R, Rooney J, Wohl AR. PMID: 28902074; PMCID: PMC5681370.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansPHPublic Health
    94. Results from the post-exposure prophylaxis pilot program (P-QUAD) demonstration project in Los Angeles County. Int J STD AIDS. 2018 05; 29(6):557-562. Beymer MR, Kofron RM, Tseng CH, Bolan RK, Flynn RP, Sayles JM, Perez MJ, Jordan WC, Landovitz RJ. PMID: 29183270; PMCID: PMC5843554.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    95. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatr. 2017 11 01; 171(11):1063-1071. Hosek SG, Landovitz RJ, Kapogiannis B, Siberry GK, Rudy B, Rutledge B, Liu N, Harris DR, Mulligan K, Zimet G, Mayer KH, Anderson P, Kiser JJ, Lally M, Brothers J, Bojan K, Rooney J, Wilson CM. PMID: 28873128; PMCID: PMC5710370.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    96. Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med. 2017 Sep 19; 167(6):384-393. Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH. PMID: 28828489; PMCID: PMC5667908.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    97. HIVR4P 2016, Partnering for Prevention: Conference Summary and Highlights. AIDS Res Hum Retroviruses. 2017 08; 33(8):749-759. Shacklett BL, Derdeyn CA, Folayan MO, Landovitz RJ, Anthony C, Behrens AJ, Hope TJ, Landais E, Leal L, Marrazzo JM, Morris L, Mugo N, Ngure K, Noseda V, Ranasinghe S, Tully DC, Voronin Y, Warren M, Wibmer CK, Xie IY, Scarlatti G, Thyagarajan B. PMID: 28649869; PMCID: PMC5564036.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    98. Differentiating Nonoccupational Postexposure Prophylaxis Seroconverters and Non-Seroconverters in a Community-Based Clinic in Los Angeles, California. Open Forum Infect Dis. 2017; 4(2):ofx061. Beymer MR, Weiss RE, Bolan RK, Kofron RM, Flynn RP, Pieribone DL, Kulkarni SP, Landovitz RJ. PMID: 28596981; PMCID: PMC5458294.
      View in: PubMed   Mentions: 8  
    99. Serious concerns regarding a meta-analysis of preexposure prophylaxis use and STI acquisition. AIDS. 2017 03 13; 31(5):739-740. Harawa NT, Holloway IW, Leibowitz A, Weiss R, Gildner J, Landovitz RJ, Perez MJ, Kulkarni S, Rotheram-Borus MJ, Shoptaw S. PMID: 28225452; PMCID: PMC5580999.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    100. Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis. 2017 Jan 15; 215(2):238-246. Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH. PMID: 27811319; PMCID: PMC5790146.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    101. An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. J Acquir Immune Defic Syndr. 2017 01 01; 74(1):21-29. Hosek SG, Rudy B, Landovitz R, Kapogiannis B, Siberry G, Rutledge B, Liu N, Brothers J, Mulligan K, Zimet G, Lally M, Mayer KH, Anderson P, Kiser J, Rooney JF, Wilson CM, Adolescent Trials Network (ATN) for HIVAIDS Interventions. PMID: 27632233; PMCID: PMC5140725.
      View in: PubMed   Mentions: 160     Fields:    Translation:HumansPHPublic Health
    102. Antiretroviral Therapy: Racial Disparities among Publicly Insured Californians with HIV. J Health Care Poor Underserved. 2017; 28(1):406-429. Landovitz RJ, Desmond KA, Leibowitz AA. PMID: 28239010; PMCID: PMC8328396.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    103. HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav. 2016 12; 20(12):2983-2995. Landovitz RJ, Tran TT, Cohn SE, Ofotokun I, Godfrey C, Kuritzkes DR, Lennox JL, Currier JS, Ribaudo HJ. PMID: 26979419; PMCID: PMC5026544.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    104. Contingent Vs. Non-Contingent Rewards: Time-Based Intervention Response Patterns Among Stimulant-Using Men Who Have Sex With Men. J Subst Abuse Treat. 2017 01; 72:19-24. Shoptaw S, Landovitz RJ, Reback CJ. PMID: 27938777; PMCID: PMC5922444.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    105. Quality of Care for HIV/AIDS and for Primary Prevention by HIV Specialists and Nonspecialists. AIDS Patient Care STDS. 2016 09; 30(9):395-408. Landovitz RJ, Desmond KA, Gildner JL, Leibowitz AA. PMID: 27610461; PMCID: PMC5035364.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsPHPublic Health
    106. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12; 316(2):191-210. Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. PMID: 27404187; PMCID: PMC5012643.
      View in: PubMed   Mentions: 273     Fields:    Translation:HumansCellsPHPublic Health
    107. Human papillomavirus infection in the oral cavity of HIV patients is not reduced by initiating antiretroviral therapy. AIDS. 2016 06 19; 30(10):1573-82. Shiboski CH, Lee A, Chen H, Webster-Cyriaque J, Seaman T, Landovitz RJ, John M, Reilly N, Naini L, Palefsky J, Jacobson MA. PMID: 26919735; PMCID: PMC4900420.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    108. Individual-Level, Partnership-Level, and Sexual Event-Level Predictors of Condom Use During Receptive Anal Intercourse Among HIV-Negative Men Who Have Sex with Men in Los Angeles. AIDS Behav. 2016 06; 20(6):1315-26. Pines HA, Gorbach PM, Weiss RE, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu RT. PMID: 26471884; PMCID: PMC4833727.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    109. Optimizing Delivery of Preexposure Prophylaxis--The Next Frontier. JAMA Intern Med. 2016 Jan; 176(1):85-6. Landovitz RJ. PMID: 26571121.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    110. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr Opin HIV AIDS. 2016 Jan; 11(1):122-8. Landovitz RJ, Kofron R, McCauley M. PMID: 26633643; PMCID: PMC4747082.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansPHPublic Health
    111. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way? J Infect Dis. 2016 May 15; 213(10):1519-20. Landovitz RJ, Grinsztejn B. PMID: 26681779.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    112. Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis. 2015 Sep; 2(3):ofv085. Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, Ofotokun I, Lennox JL, Currier JS, Olson LM, Haas DW. PMID: 26180834; PMCID: PMC4498287.
      View in: PubMed   Mentions: 10  
    113. Benefits of PrEP as an Adjunctive Method of HIV Prevention During Attempted Conception Between HIV-uninfected Women and HIV-infected Male Partners. J Infect Dis. 2015 Nov 15; 212(10):1534-43. Hoffman RM, Jaycocks A, Vardavas R, Wagner G, Lake JE, Mindry D, Currier JS, Landovitz RJ. PMID: 26092856; PMCID: PMC4621256.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    114. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation. Top Antivir Med. 2015 May-Jun; 23(2):85-90. Landovitz RJ. PMID: 26200708; PMCID: PMC6148938.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    115. Three nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2015 Mar 17; 162(6):461-2. Lennox JL, Landovitz RJ, Ribaudo HJ. PMID: 25775334.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    116. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257. Clin Infect Dis. 2015 06 15; 60(12):1842-51. Ofotokun I, Na LH, Landovitz RJ, Ribaudo HJ, McComsey GA, Godfrey C, Aweeka F, Cohn SE, Sagar M, Kuritzkes DR, Brown TT, Patterson KB, Para MF, Leavitt RY, Villasis-Keever A, Baugh BP, Lennox JL, Currier JS, AIDS Clinical Trials Group (ACTG) A5257 Team. PMID: 25767256; PMCID: PMC4660025.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCellsCTClinical Trials
    117. Perceptions of and intentions to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. Int J STD AIDS. 2015 Dec; 26(14):1040-8. Brooks RA, Landovitz RJ, Regan R, Lee SJ, Allen VC. PMID: 25638214; PMCID: PMC4520772.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansPHPublic Health
    118. Contingency management facilitates the use of postexposure prophylaxis among stimulant-using men who have sex with men. Open Forum Infect Dis. 2015 Jan; 2(1):ofu114. Landovitz RJ, Fletcher JB, Shoptaw S, Reback CJ. PMID: 25884003; PMCID: PMC4396429.
      View in: PubMed   Mentions: 14  
    119. Two years of Truvada for pre-exposure prophylaxis utilization in the US. J Int AIDS Soc. 2014; 17(4 Suppl 3):19730. Flash C, Landovitz R, Giler RM, Ng L, Magnuson D, Wooley SB, Rawlings K. PMID: 25397476; PMCID: PMC4225421.
      View in: PubMed   Mentions: 42     Fields:    
    120. Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1. Ann Intern Med. 2014 Oct 07; 161(7):I-22. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team. PMID: 25285557.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    121. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med. 2014 Oct 07; 161(7):461-71. Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS, ACTG A5257 Team. PMID: 25285539; PMCID: PMC4412467.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCellsCTClinical Trials
    122. Online Social Networking, Sexual Risk and Protective Behaviors: Considerations for Clinicians and Researchers. Curr Addict Rep. 2014 Sep; 1(3):220-228. Holloway IW, Dunlap S, Del Pino HE, Hermanstyne K, Pulsipher C, Landovitz RJ. PMID: 25642408; PMCID: PMC4309385.
      View in: PubMed   Mentions: 30  
    123. Uptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California. AIDS Res Hum Retroviruses. 2014 Sep; 30(9):848-55. Beymer MR, Bolan RK, Flynn RP, Kerrone DR, Pieribone DL, Kulkarni SP, Stitt JC, Mejia E, Landovitz RJ. PMID: 24970113; PMCID: PMC4151052.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    124. Moving HIV PrEP from research into practice. Lancet Infect Dis. 2014 Sep; 14(9):781-3. Landovitz RJ, Coates TJ. PMID: 25065858.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    125. Commercial lubricant use among HIV-negative men who have sex with men in Los Angeles: implications for the development of rectal microbicides for HIV prevention. AIDS Care. 2014; 26(12):1609-18. Pines HA, Gorbach PM, Reback CJ, Landovitz RJ, Mutchler MG, Mitsuyasu R. PMID: 25022198; PMCID: PMC4188690.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    126. Sexual risk trajectories among MSM in the United States: implications for pre-exposure prophylaxis delivery. J Acquir Immune Defic Syndr. 2014 Apr 15; 65(5):579-86. Pines HA, Gorbach PM, Weiss RE, Shoptaw S, Landovitz RJ, Javanbakht M, Ostrow DG, Stall RD, Plankey M. PMID: 24378726; PMCID: PMC4026016.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    127. Epidemiology, sexual risk behavior, and HIV prevention practices of men who have sex with men using GRINDR in Los Angeles, California. J Urban Health. 2013 Aug; 90(4):729-39. Landovitz RJ, Tseng CH, Weissman M, Haymer M, Mendenhall B, Rogers K, Veniegas R, Gorbach PM, Reback CJ, Shoptaw S. PMID: 22983721; PMCID: PMC3732683.
      View in: PubMed   Mentions: 135     Fields:    Translation:Humans
    128. Recommendations for the follow-up of study participants with breakthrough HIV infections during HIV/AIDS biomedical prevention studies. AIDS. 2013 Apr 24; 27(7):1119-28. Etter P, Landovitz R, Sibeko S, Sobieszczyk ME, Riddler SA, Karg C, Tsibris A, Schouten J. PMID: 23262497; PMCID: PMC4286368.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    129. High-risk Sexual Behavior is Associated with Post-Exposure Prophylaxis Non-adherence among Men who have Sex with Men Enrolled in a Combination Prevention Intervention. J Sex Transm Dis. 2013; 2013:210403. Fletcher JB, Rusow JA, Le H, Landovitz RJ, Reback CJ. PMID: 24527254; PMCID: PMC3920980.
      View in: PubMed   Mentions: 7  
    130. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDS. 2012 Jun; 26(6):320-8. Landovitz RJ, Fletcher JB, Inzhakova G, Lake JE, Shoptaw S, Reback CJ. PMID: 22680280; PMCID: PMC3366332.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    131. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDS. 2012 Feb; 26(2):87-94. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. PMID: 22149764; PMCID: PMC3266517.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansPHPublic Health
    132. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep. 2011 Jun; 8(2):94-103. Kelesidis T, Landovitz RJ. PMID: 21465112; PMCID: PMC3269441.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    133. Motivators, concerns, and barriers to adoption of preexposure prophylaxis for HIV prevention among gay and bisexual men in HIV-serodiscordant male relationships. AIDS Care. 2011 Sep; 23(9):1136-45. Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. PMID: 21476147; PMCID: PMC3244470.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    134. Aching for a diagnosis. J Hosp Med. 2010 Jan; 5(1):55-9. Afsarmanesh N, Nayeb-Hashemi H, Landovitz R. PMID: 20063393.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    135. Clinical practice. Postexposure prophylaxis for HIV infection. N Engl J Med. 2009 Oct 29; 361(18):1768-75. Landovitz RJ, Currier JS. PMID: 19864675.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    136. Occupational and nonoccupational postexposure prophylaxis for HIV in 2009. Top HIV Med. 2009 Jul-Aug; 17(3):104-8. Landovitz RJ. PMID: 19675368.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsPHPublic Health
    137. Availability of HIV postexposure prophylaxis services in Los Angeles County. Clin Infect Dis. 2009 Jun 01; 48(11):1624-7. Landovitz RJ, Combs KB, Currier JS. PMID: 19400685; PMCID: PMC2922974.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    138. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J Infect Dis. 2008 Oct 15; 198(8):1113-22. Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G. PMID: 18783318.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    139. Antiretroviral rounds. Immediate ART after an OI: are we there yet? AIDS Clin Care. 2008 Sep; 20(9):74-5. Grant P, Zolopa A, Landovitz RJ. PMID: 18841619.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    140. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care. 2008 Mar; 20(3):376-81. Shoptaw S, Rotheram-Fuller E, Landovitz RJ, Wang J, Moe A, Kanouse DE, Reback C. PMID: 17963091.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    141. Updated guideline for occupational postexposure prophylaxis for HIV. AIDS Clin Care. 2008 Feb; 20(2):15. Landovitz RJ. PMID: 18399011.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    142. Recent efforts in biomedical prevention of HIV. Top HIV Med. 2007 Jun-Jul; 15(3):99-103. Landovitz RJ. PMID: 17598929.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    143. Symptomatic junctional bradycardia after treatment with nelfinavir. Clin Infect Dis. 1999 Aug; 29(2):449-50. Landovitz RJ, Sax PE. PMID: 10476763.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    Raphael's Networks
    Concepts (328)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (58)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-6-g69de2244 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California